Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Detection reagent for prognosis of ZFP36 prostatic cancer and kit of detection reagent

A detection kit, a technology for prostate cancer, applied in the biological field, can solve problems such as insufficient specificity and increased PSA

Inactive Publication Date: 2015-09-02
GUIZHOU PROVINCIAL PEOPLES HOSPITAL
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, as a diagnostic indicator of prostate cancer, although PSA has strong sensitivity, its specificity is insufficient. Studies have shown that various diseases such as benign prostatic hyperplasia, prostatitis, and acute urinary retention can cause increased PSA levels in plasma.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Detection reagent for prognosis of ZFP36 prostatic cancer and kit of detection reagent
  • Detection reagent for prognosis of ZFP36 prostatic cancer and kit of detection reagent
  • Detection reagent for prognosis of ZFP36 prostatic cancer and kit of detection reagent

Examples

Experimental program
Comparison scheme
Effect test

experiment example

[0036] Experimental example: Selection experiment of markers indicative of tumor inflammatory state in prostate cancer

[0037] One: Bioinformatics data mining

[0038] 1. Using the gene chip microarray data set (Taylor dataset), SPSS 13.0 was used to analyze the expression level of ZFP36 in 150 prostate cancer tissues. The results found that the expression level of ZFP36 was the same as that of serum PSA (P < 0.001), Gleason score (P < 0.001), pathological stage (P = 0.016), metastasis (P < 0.001) and biochemical recurrence (P < 0.001) were significantly correlated, that is, patients with low serum PSA, low Gleason score, low pathological stage, no metastasis, and no biochemical recurrence ZFP36 expression was higher in vivo (see Table 1). Therefore, studies have shown that ZFP36 is involved in the complex evolution process of prostate cancer and can be used as a molecular marker for judging the inflammatory state of prostate cancer.

[0039]

[0040] 2. The results sho...

Embodiment 1

[0053] Reagent name content (1) H 2 o 2 1-1.5ml (2) Non-immune sheep serum working solution 1-1.5ml (3) Primary antibody: rabbit polyclonal antibody against ZFP36 2.5-20ul (4) Secondary antibody: biotin-labeled goat anti-rabbit IgG working solution 1ml (5) Streptavidin-peroxidase solution 1ml (6) DAB developer 2-3ml

[0054] The method of using this kit is as follows:

[0055] (1) Place the slices that have been dewaxed, hydrated, and antigen-retrieved in the incubation box, and circle the tissue with a water-blocking pen to prevent the reagents from dripping from spreading, and absorb the water on the slices with absorbent paper. , do not touch the tissue, add H 2 o 2 Cover the tissue with 50ul and incubate at room temperature for 30min to block the activity of endogenous peroxidase;

[0056] (2) Rinse with PBS for 3 minutes, repeat 3 times;

[0057] (3) Slightly absorb the PBS solution on the slice with absorbent pap...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a detection reagent for prognosis of ZFP36 prostatic cancer and a kit of the detection reagent. The reagent is prepared from the following components (for 20 people): 1-1.5ml of H2O2, 1-1.5ml of nonimmune sheep serum working solution, 2.5-20mul of primary antibodies, namely rabbit-derived anti-ZFP36 polyclonal antibodies, 1ml of secondary antibodies, namely biotin labeled sheep anti-rabbit IgG working solution, 1ml of streptomycete antibiotin-peroxidase solution, and 2-3ml of DAB color developing agent. The detection kit for the prognosis of the prostatic cancer contains the detection reagent for detecting the inflammatory status of the tumor. The detection reagent is capable of detecting the inflammatory status of the tumor; a feasible method is provided for the diagnosis of the prostatic cancer and the prediction of the postoperative recurrence transfer rate, the postoperative recurrence transfer time and the life time of a prostatic cancer patient.

Description

technical field [0001] The invention belongs to the field of biotechnology, and specifically relates to a detection reagent for prognostic diagnosis of prostate cancer, and also relates to the detection kit for prognostic diagnosis of prostate cancer. Background technique [0002] Prostate cancer is the most common malignant tumor of the male reproductive system in the world. For elderly men, its incidence rate ranks second among all malignant tumors. The incidence of prostate cancer varies greatly from country to country. The incidence of prostate cancer in the United States has surpassed that of lung cancer, becoming the highest incidence of male malignancy. Although the incidence of prostate cancer in my country is much lower than that in Europe and the United States, it has shown an obvious upward trend in recent years. [0003] In the current clinical diagnosis, the prostate specific antigen (PSA) is mainly used to distinguish prostate cancer and benign prostatic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/68
CPCG01N33/57434G01N33/57484
Inventor 朱建国袁东波张伟
Owner GUIZHOU PROVINCIAL PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com